Clinerion and Pangaea partner to improve cancer patient lives.
Summary
Pangaea’s and Clinerion’s customers, scientists and clinicians from the Biopharmaceutical industry, will be able to find patients of specific phenotypes from across these different regions at speed and with higher accuracy. Pangaea’s technology is based on the founders’ work over the last 20 years and is proven to be at least 50 times faster and 30% more accurate than alternatives such as rule-based natural language processing (NLP) or keyword searches. “Our approach is also shown to improve the quality of EHR data, which results in faster identification of patients based on phenotypes, which is critical for drug discovery, clinical trials and real-world evidence studies. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. For more information, please contact: Dr. Carlos Pittol Head of Investments and Partnerships Pangaea Data Limited Millennium Court Suite 9, 264 Waterloo Road, London SE1 8RP, United Kingdom cpittol@pangaeadata.ai
Classifications
AskAI Classifications
LabelsLinked Companies
